Nymox Reports New Results on Favorable Side Effect Profile of NX-1207 Treatment
May 21 2014 - 9:50AM
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report
new positive data confirming the advantageous side effect profile
of the Company's lead compound NX-1207. Results from the Brief Male
Sexual Function Questionnaire (BMSF) in the Company's recently
completed NX03-0040 trial of NX-1207 2.5 mg and 15 mg for the
treatment of low grade localized prostate cancer indicate that
targeted treatment with NX-1207 at either dose had no significant
effect on reported sexual function score post-treatment.
Currently approved drugs for prostate enlargement (BPH or benign
prostatic hyperplasia) can produce significant sexual side effects
such as impotence, decreased libido, ejaculation disorders, and
male breast enlargement. NX-1207 has been shown not to have these
sexual drawbacks in results to date. As well, certain of the
approved BPH drugs, including the combination drug therapies, are
also associated with an increased risk of high-grade prostate
cancer. By contrast, the area of the prostate targeted with NX-1207
treatment showed less prostate cancer progression with less
radiation and surgery due to cancer progression as compared to
controls in the recent NX03-0040 trial.
Nymox recently announced the completion of its second pivotal
Phase 3 trial of NX-1207 for BPH, NX02-0018, and top-line results
for its Phase 2 trial of NX-1207 for localized low risk prostate
cancer, NX03-0040.
NX-1207 is a novel patented drug developed by Nymox that is
administered by a urologist in an office setting directly into the
zone of the prostate to be treated. The procedure takes only a few
minutes, does not require sedation, anesthesia or catheterization,
and involves little or no pain or discomfort.
NX-1207 successfully completed a series of blinded controlled
multi-center U.S. clinical trials for BPH where a single 2.5 mg
dose of NX-1207 was found to produce at 90 days an average
improvement in standardized symptom score about double that
reported for currently approved BPH drugs without causing the
sexual or cardiovascular side effects associated with those drugs.
Follow-up studies showed evidence of long lasting benefit with a
significant proportion of men who received a single dose reporting
maintained improvement in BPH symptoms without other treatments for
up to 5 years or more.
BPH is one of the most commonly diagnosed diseases in older men.
The condition can have a significant negative impact on a man's
health and quality of life and can lead to acute urinary retention,
incontinence and other serious consequences. It is estimated that
50% of men in their 50s have pathological signs of prostatic
hyperplasia and from 26 to 46% of men between the ages of 40 to 79
years suffer from moderate to severe urinary problems and symptoms
associated with BPH.
More information about Nymox is available at www.nymox.com,
email: info@nymox.com, or 800-936-9669.
This press release contains certain "forward-looking statements"
as defined in the United States Private Securities Litigation
Reform Act of 1995 that involve a number of risks and
uncertainties. There can be no assurance that such statements will
prove to be accurate and the actual results and future events could
differ materially from management's current expectations. Such
factors are detailed from time to time in Nymox's filings with the
United States Securities and Exchange Commission and other
regulatory authorities.
CONTACT: Brian Doyle
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Sep 2023 to Sep 2024